Chad Messer
Stock Analyst at Lake Street
(0.87)
# 4,008
Out of 5,131 analysts
30
Total ratings
30%
Success rate
-15.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Buy | $22 → $32 | $20.45 | +56.48% | 2 | Dec 16, 2025 | |
| OSTX OS Therapies | Maintains: Buy | $18 → $17 | $1.54 | +1,003.90% | 2 | Nov 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $16 | $2.72 | +488.24% | 1 | Oct 21, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $106 | $63.40 | +67.19% | 1 | Sep 23, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Buy | $4 → $75 | $5.81 | +1,190.88% | 2 | Aug 15, 2025 | |
| ONCY Oncolytics Biotech | Initiates: Buy | $7 | $0.99 | +605.93% | 1 | Aug 13, 2025 | |
| COYA Coya Therapeutics | Initiates: Buy | $16 | $5.12 | +212.50% | 1 | Jul 9, 2025 | |
| LTRN Lantern Pharma | Initiates: Buy | $25 | $3.39 | +637.46% | 1 | Apr 2, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Strong Buy | $134 → $114 | $3.91 | +2,815.60% | 3 | Aug 3, 2021 | |
| CELC Celcuity | Initiates: Buy | $50 | $104.67 | -52.23% | 1 | Jul 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $48 | $63.32 | -24.19% | 2 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $44.15 | -32.05% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $72.37 | -30.91% | 1 | Jun 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $29 | $7.51 | +286.15% | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.38 | +2,501.46% | 1 | Apr 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $86 | $81.54 | +5.47% | 2 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $44 | $18.63 | +136.18% | 2 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $182 → $166 | $23.15 | +617.06% | 1 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $1.49 | +1,108.05% | 1 | May 5, 2020 |
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $22 → $32
Current: $20.45
Upside: +56.48%
OS Therapies
Nov 18, 2025
Maintains: Buy
Price Target: $18 → $17
Current: $1.54
Upside: +1,003.90%
Genelux
Oct 21, 2025
Initiates: Buy
Price Target: $16
Current: $2.72
Upside: +488.24%
Monopar Therapeutics
Sep 23, 2025
Initiates: Buy
Price Target: $106
Current: $63.40
Upside: +67.19%
Bolt Biotherapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $4 → $75
Current: $5.81
Upside: +1,190.88%
Oncolytics Biotech
Aug 13, 2025
Initiates: Buy
Price Target: $7
Current: $0.99
Upside: +605.93%
Coya Therapeutics
Jul 9, 2025
Initiates: Buy
Price Target: $16
Current: $5.12
Upside: +212.50%
Lantern Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $25
Current: $3.39
Upside: +637.46%
Esperion Therapeutics
Aug 3, 2021
Maintains: Strong Buy
Price Target: $134 → $114
Current: $3.91
Upside: +2,815.60%
Celcuity
Jul 27, 2021
Initiates: Buy
Price Target: $50
Current: $104.67
Upside: -52.23%
Jul 19, 2021
Maintains: Buy
Price Target: $33 → $48
Current: $63.32
Upside: -24.19%
Jun 28, 2021
Maintains: Buy
Price Target: $33 → $30
Current: $44.15
Upside: -32.05%
Jun 17, 2021
Initiates: Buy
Price Target: $50
Current: $72.37
Upside: -30.91%
May 14, 2021
Maintains: Buy
Price Target: $31 → $29
Current: $7.51
Upside: +286.15%
Apr 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.38
Upside: +2,501.46%
Mar 23, 2021
Maintains: Buy
Price Target: $95 → $86
Current: $81.54
Upside: +5.47%
Jan 8, 2021
Maintains: Buy
Price Target: $35 → $44
Current: $18.63
Upside: +136.18%
Jan 8, 2021
Maintains: Buy
Price Target: $182 → $166
Current: $23.15
Upside: +617.06%
May 5, 2020
Maintains: Buy
Price Target: $15 → $18
Current: $1.49
Upside: +1,108.05%